100 Bayer Road
It all starts with a friendship between two men, plenty of natural curiosity and two kitchen stoves. Businessman Friedrich Bayer and dyer Johann Friedrich Weskott use these to conduct experiments and eventually discover how to make the dye fuchsine.
On August 1, 1863, they found the "Friedr. Bayer et. comp." company in Wuppertal-Barmen, a 19th century startup with tremendous potential.
Bayer is a Life Science company with a more than 150-year history and core competencies in the areas of health care and agriculture. With our innovative products, we are contributing to finding solutions to some of the major challenges of our time.
Our goal is to create value for our customers, stockholders and employees, while also strengthening the company’s earning power. We are committed to operating sustainably and addressing our social and ethical responsibilities. Employees with a passion for innovation enjoy excellent development opportunities at Bayer.
All this goes to make up our purpose: Science for a better life.
Passion to innovate | Power to change
428 articles with Bayer
It’s hard to believe 2018 is half over. There have been plenty of interesting and important stories in the biopharma space this year. Here’s a look at our top 10 stories so far, counting down from 10 to the number one story.
EVOTEC CONFIRM CLOSING OF TRANSACTION WITH SANOFI TO ACCELERATE INFECTIOUS DISEASE RESEARCH AND DEVELOPMENT
Evotec AG today announced that the strategic transaction to integrate Sanofi's infectious disease unit including licensing-in the majority of Sanofi's infectious disease research portfolio, has been successfully closed with effect from 01 July 2018.
Bayer Launches 'myMentor' Peer-to-Peer Support Program for Patients with Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension
Bayer announced the launch of myMentor
Platelet Biogenesis (PBG) was awarded a two-year, $3.5 million grant from the U.S. Department of Defense (DoD). The funds are to support the company’s proprietary bioreactor to produce therapeutic amounts of platelets.
There are several recent announcements of German companies opening laboratories in the U.S.
Bayer and MD Anderson Cancer Center Collaborate to Strengthen Oncology Translational Research and Clinical Development
Five-year agreement to accelerate early clinical development of selected Bayer drug candidates
U.S. Justice Department gave the merger the go-ahead after Monsanto agreed to sell approximately $9 billion in assets.
Bayer Partners with U.S. Department of Energy to Produce Key Starting Material for Xofigo® (radium Ra 223 dichloride) Injection
Department of Energy's Oak Ridge National Laboratory to supply actinium-227
Bayer announced today that the U.S.Food and Drug Administration (FDA) has accepted the New Drug Application (NDA).
Curis Expands Senior Management Expertise with Appointment of Robert Martell, M.D., Ph.D., as Head of Research and Development
Curis, Inc. today announced that Robert Martell, M.D., Ph.D., has been appointed Head of Research and Development.
Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) announced today that Evotec and Celgene Corporation ("Celgene") have entered into a long-term strategic drug discovery and development partnership to identify new therapeutics in oncology.
Pharma and biotech companies across the globe continued to expand and reshape their leadership teams with new hires this past week. BioSpace collected several announced leadership appointments, which includes new chief executive officers, new members to boards of directors and more.
Bayer to Present Pulmonary Hypertension Data at the American Thoracic Society 2018 International Conference
Bayer announced today that clinical data from its pulmonary disease franchise will be presented in scientific sessions at the 2018 American Thoracic Society (ATS) International Conference, May 18-23rd in San Diego, CA.
Genentech reported that its Phase III IMblaze370 trial of Tecentriq (atezolizumab) and Cotellic (cobimetinib) for difficult-to-treat, locally advanced or metastatic colorectal cancer (CRC) did not meet its primary endpoint of overall survival (OS) compared to Bayer’s Stivarga (regorafenib).
Some accelerators come out of government and academic institutions, while others have specific big pharma backing. Many use a combination of all of the above, while some are private in nature linked to venture capital firms. Let’s look at some of the accelerators linked to big pharma.
The Digital Therapeutics Alliance (DTA) welcomes nine companies to membership
At the World Medical Innovation Forum, panelists observed that AI can be used to scour old clinical trial data for new applications and possibly take over part of clinical trials in “virtual” models.
Claritin® Launches 20 Minutes of Spring Project with Actress Hilary Duff and Boys & Girls Clubs of America
The makers of Claritin® launched their 20 Minutes of Spring Project with actress Hilary Duff and Boys & Girls Clubs of America, the nation's leading youth service organization.
Bayer Earns National Recognition as Diversity and Inclusion Leader in America's 2018 "Best-of-the-Best" Corporations
Bayer has earned a place on the annual Best-of-the-Best list of corporations in America committed to diversity and inclusion across all communities.
Harborview Farms is launching today as the latest Bayer ForwardFarm - the first in North America.